SCHEMBL923707

SCHEMBL923707

O=C1[C]CC2C=CC=CC2N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL460791 0.68 ITGB3 (0.30)
SCHEMBL1032285 0.65 TDO2 (0.40)
Water SCHEMBL10621554 0.64 GAA (0.31)
SCHEMBL19032024 0.63
SCHEMBL4276731 0.63
Hydrochloric Acid SCHEMBL10660266 0.63 GAA (0.30)
SCHEMBL56056 0.63
SCHEMBL12993233 0.62
SCHEMBL10555075 0.62
SCHEMBL3801333 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49361-E1 Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2023-01-10 US claimed
US-11339193-B2 CDP protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2022-05-24 US claimed
US-20220048910-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2022-02-17 US claimed
EP-3946345-A1 METHODS OF TREATING NEUROPATHIC PAIN Intra-Cellular Therapies, Inc. (US) 2022-02-09 EP claimed
CN-113905737-A Method of treating neuropathic pain 细胞内治疗公司 2022-01-07 CN claimed
EP-3914235-A2 METHODS OF TREATING ADDICTION Intra-Cellular Therapies, Inc. (US) 2021-12-01 EP claimed
EP-3897621-A1 ORGANIC COMPOUNDS Intra-Cellular Therapies, Inc. (US) 2021-10-27 EP claimed
CN-113329742-A Method for treating addiction 细胞内治疗公司 2021-08-31 CN claimed
CN-112513065-A CDP protein secretion inhibitors 科智生命科学公司 2021-03-16 CN claimed
EP-3774850-A1 CDP PROTEIN SECRETION INHIBITORS Kezar Life Sciences (US) 2021-02-17 EP claimed
EP-3191477-A1 FUSED BICYCLIC (HETERO)AROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS Redx Pharma Plc (GB) 2017-07-19 EP claimed
WO-2016038389-A1 FUSED BICYCLIC (HETERO)AROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS REDX PHARMA PLC (GB) 2016-03-17 WO claimed
US-8071772-B2 Spirolactam bicyclic CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US claimed
US-8071771-B2 Bicyclic spirohydantoin CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-12-06 US claimed
US-20090325991-A1 Spirolactam Bicyclic CGRP Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-31 US claimed
US-20090176757-A1 Bicyclic Spirohydantoin CGRP Receptor Antagonists MERCK SHARP & DOHME LLC 2009-07-09 US claimed
EP-1954268-A2 SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2008-08-13 EP claimed
EP-1951228-A2 BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2008-08-06 EP claimed
WO-2007061695-A2 BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-05-31 WO claimed
WO-2007061696-A2 SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-05-31 WO claimed